Study record

Mitochondrial-derived microproteins in lung disease: insights and implications

Behan M, Yen K, Cohen P et al. · Am J Physiol Lung Cell Mol Physiol · 2026

ReviewSeveralEvidence tier R

What this study reported

Reviewed published work on mitochondrial-derived microproteins, noting that most of it concerns MOTS-c and humanin in high-mitochondrial-density tissues and in age-related disease rather than in the lung. Summarised reported mitochondrial, nuclear and extracellular actions of these peptides and how their levels have been reported to change across disease states. Identified gaps in the literature on acute lung injury, chronic obstructive pulmonary disease, allergic asthma and pulmonary fibrosis.

Limitations

Narrative review with no stated search strategy, largely a gap analysis because little primary pulmonary data on MOTS-c exists, and MOTS-c is discussed alongside other microproteins rather than appraised on its own.

Study record

Annotated fields for this study
Study modelReview
Substance studiedSeveralMore than one of these is central to the paper (common for reviews).
SpeciesNot reported
System studiedPublished literature on mitochondrial-derived microproteins in lung homeostasis and lung disease
PopulationNot reported
DesignNarrative review
Sample size as reportedNot reported
Control groupNot reported
Route (data field only)Not reported
Endpoints measuredreported mitochondrial, nuclear and extracellular actions of MDPs; MDP levels across disease states; knowledge gaps in acute lung injury, COPD, allergic asthma and pulmonary fibrosis
Pathways measuredNot reported
Research areasLung · Mitochondrial biology
Evidence tierR — Review (context, not evidence)
Publication typesJournal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Indirect
Model applicability
n/a
Sample size
n/a
Controls
n/a
Outcome validity
n/a
Support for its own conclusion
Weak

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.